Literature DB >> 28274800

A screening tool to detect clinical manganese neurotoxicity.

Brad A Racette1, Anat Gross2, Susan R Criswell2, Harvey Checkoway3, Susan Searles Nielsen2.   

Abstract

Manganese (Mn) over-exposure in occupational settings is associated with basal ganglia toxicity and a movement disorder characterized by parkinsonism (i.e., the signs and symptoms of Parkinson disease). A simple test to help non-neurologists identify workers with clinical Mn neurotoxicity represents an unmet need. In a cohort of Mn-exposed workers from welding worksites, with extensive clinical data, we developed a linear regression model to predict the Unified Parkinson Disease Rating Scale motor subsection part 3 (UPDRS3) score. We primarily considered factors easily obtained in a primary care or occupational medicine clinic, specifically easily assessed signs of parkinsonism and factors likely to be associated with UPDRS3 such as age, timed motor task results, and selected symptoms/conditions. Secondarily we considered other demographic variables and welding exposure. We based the model on 596 examined workers age≤65years and with timed motor task data. We selected the model based on simplicity for clinical application, biologic plausibility, and statistical significance and magnitude of regression coefficients. The model contained age, timed motor task scores for each hand, and indicators of action tremor, speech difficulty, anxiety, depression, loneliness, pain and current cigarette smoking. When we examined how well the model identified workers with clinically significant parkinsonism (UPDRS3≥15) the receiver operating characteristic area under the curve (AUC) was 0.72 (95% confidence interval [CI] 0.67, 0.77). With a cut point that provided 80% sensitivity, specificity was 52%, the positive predictive value in our cohort was 29%, and the negative predictive value was 92%. Using the same cut point for predicted UPDRS3, the AUC was nearly identical for UPDRS3≥10, and was 0.83 (95% CI 0.76, 0.90) for UPDRS3≥20. Since welding exposure data was not required after including its putative effects, this model may help identify workers with clinically significant Mn neurotoxicity in a variety of settings, as a first step in a tiered occupational screening program.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Manganese; Parkinsonism; Predictive model; Welding

Mesh:

Year:  2017        PMID: 28274800      PMCID: PMC5587364          DOI: 10.1016/j.neuro.2017.02.009

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  29 in total

1.  Estimating the prevalence of clinical manganism using a cascaded screening process in a South African manganese smelter.

Authors:  J E Myers; J Fine; D Ormond-Brown; J Fry; A Thomson; M L Thompson
Journal:  Neurotoxicology       Date:  2009-08-28       Impact factor: 4.294

2.  Manganese exposure: neuropsychological and neurological symptoms and effects in welders.

Authors:  Rosemarie M Bowler; Sabine Gysens; Emily Diamond; Sanae Nakagawa; Marija Drezgic; Harry A Roels
Journal:  Neurotoxicology       Date:  2005-12-15       Impact factor: 4.294

3.  Environmental tobacco smoke and Parkinson's disease.

Authors:  Susan Searles Nielsen; Lisa G Gallagher; Jessica I Lundin; W T Longstreth; Terri Smith-Weller; Gary M Franklin; Phillip D Swanson; Harvey Checkoway
Journal:  Mov Disord       Date:  2011-11-16       Impact factor: 10.338

4.  Longitudinal T1 relaxation rate (R1) captures changes in short-term Mn exposure in welders.

Authors:  Mechelle M Lewis; Michael R Flynn; Eun-Young Lee; Scott Van Buren; Eric Van Buren; Guangwei Du; Rebecca C Fry; Amy H Herring; Lan Kong; Richard B Mailman; Xuemei Huang
Journal:  Neurotoxicology       Date:  2016-08-24       Impact factor: 4.294

Review 5.  Manganism and idiopathic parkinsonism: similarities and differences.

Authors:  D B Calne; N S Chu; C C Huang; C S Lu; W Olanow
Journal:  Neurology       Date:  1994-09       Impact factor: 9.910

6.  Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

7.  Screening Parkinson's disease: a validated questionnaire of high specificity and sensitivity.

Authors:  J Duarte; L E Clavería; J de Pedro-Cuesta; A P Sempere; F Coria; D B Calne
Journal:  Mov Disord       Date:  1995-09       Impact factor: 10.338

8.  Epidemiological survey among workers exposed to manganese: effects on lung, central nervous system, and some biological indices.

Authors:  H Roels; R Lauwerys; J P Buchet; P Genet; M J Sarhan; I Hanotiau; M de Fays; A Bernard; D Stanescu
Journal:  Am J Ind Med       Date:  1987       Impact factor: 2.214

9.  Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.

Authors:  Anette Schrag; Uzma Faisal Siddiqui; Zacharias Anastasiou; Daniel Weintraub; Jonathan M Schott
Journal:  Lancet Neurol       Date:  2016-11-18       Impact factor: 44.182

10.  Dose-dependent progression of parkinsonism in manganese-exposed welders.

Authors:  Brad A Racette; Susan Searles Nielsen; Susan R Criswell; Lianne Sheppard; Noah Seixas; Mark N Warden; Harvey Checkoway
Journal:  Neurology       Date:  2016-12-28       Impact factor: 9.910

View more
  2 in total

1.  Neurotoxicity of manganese: Indications for future research and public health intervention from the Manganese 2016 conference.

Authors:  Roberto G Lucchini; Michael Aschner; Philip J Landrigan; Joan M Cranmer
Journal:  Neurotoxicology       Date:  2018-02-03       Impact factor: 4.294

2.  A Rapid Motor Task-Based Screening Tool for Parkinsonism in Community-Based Studies.

Authors:  Wendy W Dlamini; Searles Nielsen; Mwiza Ushe; Gill Nelson; Brad A Racette
Journal:  Front Neurol       Date:  2021-05-13       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.